Biotechnology Licensing: How Has the Balance of Power Shifted?Decision ResourcesOctober 21, 2005 19 Pages - SKU: DECR1212075 |
| An analysis of the pipelines of four "mega corporations" that emerged during the first half of the decade-AstraZeneca, GlaxoSmithKline, Pfizer, and Sanofi-Aventis-shows that although spending on R&D increased significantly between 1999 and 2004, the number of new chemical entities in late-stage research has declined for all four mega corporations. How successful has the pipeline enhancement process been in practice? This report examines the pipelines of the four mega corporations to see what lessons can be learned. We seek to determine the impact that the megamergers have had on pipelines-whether mergers have resulted in a greater "breadth" of activity across therapy areas and increased productivity or whether the amalgamation of pipelines has had a deleterious effect on R&D output. The question is vital for these corporations because their profitability over the coming decades will depend, to a considerable extent, on the ability of their R&D operations to bring new drugs to market.
Please note: the PDF e-mail from publisher version of this report is for a global site license. |
Related Markets
- Biotechnology
- General Biotechnology
- Business Services & Administration
- Intellectual Property
- Pharmaceuticals
- Manufacturing, Packaging & Detailing
Manufacturing, Packaging & Detailing Reports
- Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
- Perspective: TAKE Solutions Gives Leading Pharma an Edge in Drug Serialization
- The World Market for Over The Counter (OTC) Drugs
- Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
- Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
